Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018) [0.03%]
选择性COX-2抑制剂作为抗癌药物的专利回顾(2014-2018)
Sayyed Mohammad Ismail Mahboubi Rabbani,Afshin Zarghi
Sayyed Mohammad Ismail Mahboubi Rabbani
Introduction: COX-2 is a key enzyme in the process of prostaglandins (PGs) synthesis. The products of this enzyme could play a major role as the mediators of the inflammatory response and some other medical states such as...
Therapeutic and cosmetic applications of mangiferin: an updated patent review (patents published after 2013) [0.03%]
芒果儿素的治疗和美容应用：一项专利回顾(2013年后发表的专利)
Farha Quadri,Manasi Telang,Anita Mandhare
Farha Quadri
Introduction: Mangiferin and its derivatives possess diverse biological activities and desirable drug like properties. In continuation with the authors' previous publication, the present study reviews recently published p...
Androgen receptor modulators: a review of recent patents and reports (2012-2018) [0.03%]
雄激素受体调节剂专利和报道近期研究综述(2012-2018)
Shinya Fujii,Hiroyuki Kagechika
Shinya Fujii
Introduction: Androgen receptor (AR) is one of the most promising targets of drug discovery because of its importance in male reproductive systems and homeostasis of bone and muscle. Various AR-modulating agents have been...
Marcello Leopoldo,Patrizia Nardulli,Marialessandra Contino et al.
Marcello Leopoldo et al.
Introduction: P-glycoprotein is a complex ATP-ase transporter involved in physiological and pathological functions. In particular, it is involved in the onset of multidrug resistance in cancer, in ocular disease, Chronic ...
Xiao-Na Wang,Xiao-Xuan Su,Sui-Qi Cheng et al.
Xiao-Na Wang et al.
Introduction: The important role of MYC in tumorigenesis makes it particularly important to design MYC modulators. Over the past decade, researchers have raised a number of strategies for designing MYC modulators, some of...
Effects of boron-containing compounds on immune responses: review and patenting trends [0.03%]
含硼化合物对免疫反应的影响：综述与专利趋势分析
Karla S Romero-Aguilar,Ivonne M Arciniega-Martínez,Eunice D Farfán-García et al.
Karla S Romero-Aguilar et al.
Introduction: Boron-containing compounds induce effects on immune responses. Such effects are interesting to the biomedical field for the development of therapeutic tools to modulate the immune system. ...
An updated patent review of therapeutic applications of chalcone derivatives (2014-present) [0.03%]
2014年至今治疗应用查尔康素衍生物专利回顾
Debarshi Kar Mahapatra,Vivek Asati,Sanjay Kumar Bharti
Debarshi Kar Mahapatra
Introduction: Chalcone or benzylideneacetophenone or 1,3-diphenyl-2-propene-1-one is a natural product comprising of two aromatic rings connected together by a three-carbon α, β unsaturated carbonyl bridge. It is one of...
SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018) [0.03%]
糖尿病治疗的SGLT2抑制剂专利回顾(2013-2018)
Jyotsana Pandey,Akhilesh K Tamrakar
Jyotsana Pandey
Introduction: The sodium-glucose co-transporter 2 (SGLT2) is ascribed to target renal tubular glucose re-absorption, and its inhibition has been proved to induce glucosuria which improves the glycemic index. Accordingly, ...
Sarah A Holstein
Sarah A Holstein
Introduction: Bisphosphonates (BPs) are widely used to manage a variety of bone disorders, including osteoporosis, metastatic bone disease and myeloma bone disease. The nitrogen-containing BPs (NBPs) target osteoclast act...
Patent landscape of molecular and cellular targeted therapies for recessive dystrophic epidermolysis bullosa [0.03%]
recessive dystrophic epidermolysis bullosa分子和细胞靶向疗法专利布局分析
Mariel Dourado Alcorte,Mari Cleide Sogayar,Marcos Angelo Demasi
Mariel Dourado Alcorte
Introduction: Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a monogenetic inherited genodermatosis associated with deleterious mutations in the gene encoding type VII collagen (COL7A1). COL7A1 is essential for prom...